SKIN
SkinHealth Systems Inc.
SKIN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
SKIN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Strong |
SKIN's balance sheet is currently strong, and its revenue, profitability and cash flow are stable.
SKIN PE Valuation
SKIN has no meaningful PE right now: it lost money over the past year.
SKIN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SKIN's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
SKIN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.94 | +$2.12 |
| Q2 2026 | -$3.60 | +$1.66 |
| Q1 2026 | -$2.60 | +$5.26 |
SKIN is still losing money, but far less than before: $1.94 per share over the past year, against $99.60 at its worst in early 2022.
SKIN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $69.2M | -2.1% |
| Q2 2026 | $72.1M | -7.8% |
| Q1 2026 | $64.9M | -6.7% |
| Q4 2025 | $82.4M | -1.3% |
| Q3 2025 | $70.7M | -10% |
| Q2 2025 | $78.2M | -14% |
| Q1 2025 | $69.6M | -15% |
| Q4 2024 | $83.5M | -14% |
SKIN's revenue has slid since its 2023 peak: $69M last quarter, down 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.2% | +16 points |
| Q2 2026 | 5% | +8.4 points |
| Q1 2026 | -2.8% | +15 points |
| Q4 2025 | 0.2% | +8.8 points |
| Q3 2025 | -8.8% | +19 points |
| Q2 2025 | -3.5% | +21 points |
| Q1 2025 | -17% | +3.6 points |
| Q4 2024 | -8.6% | +10 points |
SKIN's operating margin was 7.2% last quarter, up 16 points from the same quarter a year ago, near the top of its range since 2021.
SKIN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.2M | +16% |
| Q2 2026 | $2.2M | -77% |
| Q1 2026 | -$5.8M | -296% |
| Q4 2025 | $15.1M | -8.2% |
| Q3 2025 | $9.6M | -6.7% |
| Q2 2025 | $9.6M | +63% |
| Q1 2025 | $3M | +$20.1M |
| Q4 2024 | $16.4M | +$21.6M |
SKIN still generates free cash flow, though less than at its 2023 peak: $23M over the past year.
SKIN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +30.3K shares |
| 1 year | +2.6% | +166K shares |
| 3 years | -1.9% | -126K shares |
| 5 years | +1032% | +5.9M shares |
SKIN has 7M diluted shares, up 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $30.2M |
| Q4 2022 | $80M |
| Q4 2021 | — |
SKIN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.8x | Net Cash |
| Q2 2026 | -13.5x | Net Cash |
| Q1 2026 | -21.9x | Net Cash |
| Q4 2025 | -7,050.7x | Net Cash |
SKIN has more cash than debt.
SKIN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.9 | Neutral |
| Stochastic | 58.5 | Neutral |
SKIN's weekly RSI is 54 (neutral) and its Stochastic is 59 (neutral).
SKIN PE vs Healthcare Sector
SKIN has no meaningful PE right now: it lost money over the past year.
SKIN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.5 | 28% above |
| 20 week MA | $13.6 | 17% above |
| 50 week MA | $18.1 | 12% below |
| 100 week MA | $25.2 | 37% below |
| 200 week MA | $64.3 | 75% below |
SKIN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 75% below its 200-week average.
SKIN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $204.2 | $223.0 | +9.2% |
| 2021 | $223.0 | $463.0 | +108% |
| 2022 | $463.0 | $180.8 | -61% |
| 2023 | $180.8 | $62.2 | -66% |
| 2024 | $62.2 | $32.4 | -48% |
| 2025 | $32.4 | $29.2 | -9.9% |
| 2026 YTD | $29.2 | $16.0 | -45% |
SKIN has finished four years in a row lower, and it's down 45% so far in 2026.